We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Joe Biden’s coronavirus tsar says Chinese vaccines are ‘not as good’ as alternatives
Northwest Biotherapeutics claims Citadel Securities, Virtu and others drove down its share price
Japanese company refuses to rule out possibility treatment contributed to brain bleeds
Cepi releases blueprint to move three times faster against a new virus than during Covid-19 pandemic
A story of cancer scares, secretive short sellers, psychological tape bombs and post-investment stress disorder
Shares fall 11% following two patient deaths in trials of lecanemab
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down
A sharp drop in local shares highlights the risks stemming from unpredictable politics
Results from UK-wide trials on anticoagulant Apixaban set to change protocols around the world
Bionaut Labs has raised $43.2mn in second financing round to fund first clinical trials
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Medicines are often given for viral infections such as flu, for which they are useless, but can cause side effects
Eli Lilly seeks approval for weight loss medication as Novo Nordisk battles supply crunch for Wegovy
Biggest shake-up in pharma pricing in decades prompts companies to shelve some potential therapies
Agreement to limit the size of the NHS drugs bill under strain
Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease
US drugs maker also says low pricing of NHS purchases risks harming Britain’s push in life sciences
Few countries have well funded plans to tackle health threat to millions
Plan abandoned almost two years after initial approval in UK and Europe
Brash new investors are clashing with the pioneers of mind-altering drug therapies
Price tag of between $70 and $300 a dose helps push Danish biotech to ‘all-time high revenues’
Ending of pharma group’s IP truce spells fight for future of mRNA technology
Legal, societal and financial barriers block treatments that can reduce risk of overdose
Fall from €3.2bn in the third quarter of 2021 to €1.8bn
Plus, COP27 gets under way and inflation is the main theme of economic news
International Edition
